Table 4.
Strong expression of PI3K/AKT/mTOR pathway proteins in HCC patients both in tumor and adjacent cirrhosis according to CLD etiology.
| Etiology | PI3K | AKT | mTOR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Tumor n (%) | Cirrhosis n (%) | p value | Tumor n (%) | Cirrhosis n (%) | p value | Tumor n (%) | Cirrhosis n (%) | p value | |
| Viral | 14/39 (35.9) | 3/27 (11.1) | 0.048b | 16/41 (39.0) | 14/35 (40.0) | 1.000b | 10/41 (24.4)< | 6/32 (18.8) | 0.769b |
| Nonviral | 21/30 (53.8) | 8/33 (24.2) | <0.001b | 15/39 (38.5) | 15/29 (51.7) | 0.399b | 6/39 (15.4) | 4/32 (12.5) | 1.000b |
| p value | 0.111a | 0.315b | — | 0.959a | 0.348a | — | 0.314a | 0.491a | — |
Data are expressed as the absolute number/total of samples analyzed (percentage). HCC, hepatocellular carcinoma; CLD, chronic liver disease. aChi-square test. bFisher's exact test.